NICE recommends use of Tagrisso (osimertinib) in non-small-cell lung cancer in adults whose disease has progressed only after first-line treatment with an EGFR tyrosine kinase inhibitor- AstraZeneca
Tagrisso (osimertinib), from AstraZeneca, is recommended by the UK NICE (National Institute for Health and Care Excellence)as an option for use within the Cancer Drugs Fund for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed only after first-line treatment with an EGFR tyrosine kinase inhibitor and if the conditions in the managed access agreement for osimertinib are followed.
The committee concluded that because the estimates of overall survival were so immature and not sufficiently robust, and the uncertainty in the clinical- and cost-effectiveness data too great, it could not recommend osimertinib for routine use in the NHS for treating EGFR T790M mutation-positive NSCLC.
The most common adverse reactions associated with osimertinib include diarrhoea, rash, dry skin, and a reduction in platelet count and some white blood cells. The committee concluded that osimertinib was a well-tolerated treatment in this group compared with cytotoxic chemotherapies such as platinum-doublet chemotherapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins